Related Experiment Videos
[3H]TCP binding sites in Alzheimer's disease
Neuroscience Letters
|January 14, 1987
Summary
Researchers studied [3H]1-[1-(2-thienyl)-cyclohexyl]piperidine ([3H]TCP) binding sites in Alzheimer's disease (AD) brains. Some AD patients showed significant declines in [3H]TCP binding in the hippocampus CA1 region, linked to severe cell loss.
Area of Science:
- Neuroscience
- Neuropathology
Background:
- Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive cognitive decline.
- The hippocampus, particularly the CA1 region, is critically involved in memory and is vulnerable in AD.
Purpose of the Study:
- To investigate the density and distribution of [3H]1-[1-(2-thienyl)-cyclohexyl]piperidine ([3H]TCP) binding sites in the human hippocampus of control and AD patients.
Main Methods:
- Quantitative autoradiography was employed to analyze [3H]TCP binding site density in human hippocampal tissue sections.
- Tissue samples were obtained from both control individuals and patients diagnosed with Alzheimer's disease.
Main Results:
- While some AD cases showed no change, others exhibited substantial reductions in [3H]TCP binding sites within the hippocampal CA1 region.
- An average decrease of 40% in [3H]TCP binding was observed in the CA1 region of AD patients, with other hippocampal areas unaffected.
Conclusions:
- The observed loss of [3H]TCP binding sites in the hippocampal CA1 region of certain AD cases may correlate with significant neuronal loss.
- This finding suggests a potential link between specific receptor binding site alterations and the severity of neuropathology in Alzheimer's disease.